Analytical Data
-
基因名
AF1521
- Application
-
别名
AF_1521
-
种属
Pan-species (General)
-
表达系统
E. coli
-
标签
Two N- s, His- & SUMO-
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O28751
-
表达区间
Met1~Leu192
-
分子量
38kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
AF1521 is a recombinant protein derived from a specific bacterial strain, which has garnered attention due to its potential therapeutic applications and role in various biochemical processes. The research background of AF1521 is rooted in the growing need for efficient proteins that can be used in drug development, diagnostics, and biotechnological applications. Studies have indicated that AF1521 may possess unique properties that enable it to exhibit significant biological activity, making it a candidate for further exploration in functional assays and structural biology. The protein's ability to interact with cellular pathways and its stability make it a promising target for the development of new therapies aimed at treating various diseases, including metabolic disorders and infectious diseases. Researchers are focusing on elucidating the protein's mechanism of action, optimizing expression systems for large-scale production, and characterizing its structure-function relationship. Overall, the investigation of AF1521 not only advances our understanding of recombinant protein technology but also enhances the potential for novel clinical applications.
